Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years - 26/01/22
, Bryony J. Simcock, MD, FRANZCOG a, b, Carrie R. Innes, PhD a, Dianne Harker, MA, RN a, Jonathan A. Williman, PhD c, Martin Whitehead, MbChB, FRCPA d, e, Rachael A. van der Griend, MbChB, FRCPA e, Beverley A. Lawton, MbChB f, Merilyn Hibma, PhD g, Peter Fitzgerald, MbChB FRCPA, FIAC h, Narena M. Dudley, MbChB, FRANZCOG i, Simone Petrich, MD, FRANZCOG j, Lois Eva, MD, FRANZCOG k, Cecile Bergzoll, MD, FRANZCOG k, Jyoti Kathuria, FRCOG, FRANZCOG l, Georgina McPherson, NP, MN, DHSc m, Amanda Tristram, MbChB, MRCOG, MD, FRANZCOG n, Jim Faherty, MD, FRANZCOG, FACOG o, Donna Hardie, FRANZCOG p, Anne Robertson, MbChB, MSc, FRANZCOG q, Vicki Robertson, FRANZCOG r, Selvan Pather, MbChB, FRANZCOG s, t, C. David Wrede, FRCS, FRCOG u, v, Flora Gastrell, MbChB, BMedSc, FRANZCOG w, Gary Fentiman, MD, FRANZCOG, LFACOG w, Michael John, FRANZCOG x, Elaine White, MbChB, MRCOG, FRANZCOG y, Catherine Parker, FRANZCOG z, Lynn Sadler, MbChB, MPH k, aaAbstract |
Background |
A number of retrospective and prospective studies have documented substantial rates of regression in cervical intraepithelial neoplasia grade 2 lesions in young women. Initial observational management of cervical intraepithelial neoplasia grade 2 is increasingly accepted as appropriate for women under 25 years of age with screen-detected abnormalities and is included in a number of clinical guidelines. However, there has been a paucity of large prospective studies on observational management with strict inclusion criteria. A number of important questions remain, specifically regarding the clinical variables that are associated with the risk of progression or persistence of disease. To investigate these factors and to ensure that young women with cervical intraepithelial neoplasia grade 2 undergoing observational management were being managed in a well-monitored and an appropriately informed fashion, we conducted a large, multicenter prospective study on observational management of cervical intraepithelial neoplasia grade 2 in women under 25 years.
Objective |
This study aimed to determine the regression rates and clinical, cytologic, and pathologic predictors of regression of cervical intraepithelial neoplasia grade 2 in women under 25 years undergoing observational management over 24 months.
Study Design |
This study was a multicenter prospective study on observational management of cervical intraepithelial neoplasia grade 2 (ie, repeat colposcopy, cytology, and cervical biopsy every 6 months) for up to 24 months. A total of 615 consenting women under 25 years with newly-diagnosed, biopsy-proven cervical intraepithelial neoplasia grade 2 were recruited (from 2010 to 2016) through 16 hospital-based colposcopy units in New Zealand and Australia.
Results |
At completion, 326 women had confirmed regression, 156 had persistent high-grade cervical intraepithelial neoplasia grade 2 or 3 or adenocarcinoma in situ, and 24 had unconfirmed regression (ie, first regression at the 24-month follow-up). A total of 109 women did not complete the protocol (41 because of delayed follow-up, 41 lost to follow-up, 22 elected treatment, 4 refused a biopsy, and 1 died of an unrelated cause). Confirmed regression was observed in 53% (326 of 615) of all women enrolled in the study and, when missing data were imputed, it was estimated that 64% of women (95% confidence interval, 60%–68%) would have experienced regression. Similarly, lesions regressed in 64% (326 of 506) of women who completed the observational protocol. Based on a multivariable analysis, detection of human papillomavirus 16 in a liquid-based cytology sample at the time of initial colposcopy decreased the chance of regression by 31% (risk ratio, 0.69; 95% confidence interval, 0.56–0.86; P<.001). In addition, at initial colposcopy, low-grade or normal colposcopic impression, later year of diagnosis, low-grade or normal cytology, and being a nonsmoker were all independently associated with an increased chance of regression.
Conclusion |
More than half of women under 25 years with cervical intraepithelial neoplasia grade 2 will regress to cervical intraepithelial neoplasia grade 1 or normal within 24 months without destructive treatment. The absence of human papillomavirus 16 is the most important predictor of regression.
Le texte complet de cet article est disponible en PDF.Key words : cervical abnormalities, observational management, prospective multicenter study, young women
Plan
| G.F. is a retired fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists. |
|
| P.H.S. and B.J.S. report receiving research grants from the Health Research Council of New Zealand and Cancer Society of New Zealand. C.R.I. reports receiving nonfinancial support from Seqirus (NZ) Ltd. M.H. reports receiving a grant from the Health Research Council of New Zealand. B.A.L. reports receiving research grants from the Health Research Council of New Zealand and Cancer Society of New Zealand, personal fees and nonfinancial support from Seqirus (NZ) Ltd, unrelated to this study, and previously sitting on the Australasian Pfizer board for women’s menopause health. The remaining authors report no conflict of interest. |
|
| This study was funded by grants from the Health Research Council of New Zealand (HRC 13/143) and Cancer Society of New Zealand (CS 12/30). Neither of the sponsors had any input in the study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the article for publication. |
|
| Data for this observational study were obtained from The Prediction of Regression in CIN2 (PRINCess) study that was approved on April 14, 2010, by the Multi-Region Ethics Committee (ethics reference, MEC/09/07/079) and had site-specific local authorization. The PRINCess protocol is available at otago073807.pdf. |
|
| P.H.S. (the manuscript’s guarantor) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study protocol have been explained. |
|
| Cite this article as: Sykes PH, Simcock BJ, Innes CR, et al. Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years. Am J Obstet Gynecol 2022;226:222.e1-13. |
Vol 226 - N° 2
P. 222.e1-222.e13 - février 2022 Retour au numéro
Article précédent
- Ovarian cancer incidence and death in average-risk women undergoing bilateral salpingo-oophorectomy at benign hysterectomy
- Maria C. Cusimano, Sarah E. Ferguson, Rahim Moineddin, Maria Chiu, Suriya Aktar, Ning Liu, Nancy N. Baxter
- Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis
- Andrew T. Gustin, Andrea R. Thurman, Neelima Chandra, Luca Schifanella, Maria Alcaide, Raina Fichorova, Gustavo F. Doncel, Michael Gale, Nichole R. Klatt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?